New Wave of Therapies Targets Deadly Liver Disease MASH From Multiple Angles
A 2025 review maps the most promising drug targets and novel strategies—from gene therapy to gut microbiome interventions—for treating MASH.
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease tied to obesity, type 2 diabetes, and heart disease, yet effective treatments remain scarce. A 2025 review in Drug Discovery Today surveys the emerging therapeutic landscape, highlighting drugs that target metabolic receptors such as THR-β, FXR, PPAR, GLP-1 receptor agonists, FGF21 analogs, and SGLT2 inhibitors. Beyond pharmacology, the review covers cutting-edge approaches including siRNA gene silencing, probiotics, fecal microbiota transplantation, and stem cell therapy. Researchers emphasize that multi-targeted treatment strategies addressing fibrosis, inflammation, and lipid metabolism simultaneously appear most promising, while better non-invasive diagnostics and long-term safety data remain critical unmet needs.
Detailed Summary
Metabolic dysfunction-associated steatohepatitis (MASH)—formerly known as NASH—is the aggressive, inflammation-driven stage of fatty liver disease increasingly prevalent alongside the global obesity and type 2 diabetes epidemics. Left untreated, MASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Despite its growing burden, only one drug (resmetirom) has received regulatory approval, making the search for effective therapies urgent.
This 2025 narrative review from researchers at the National Institute of Pharmaceutical Education and Research (India) systematically maps the mechanistic targets and therapeutic candidates showing the greatest promise. The paper covers a broad pharmacological spectrum: thyroid hormone receptor-beta (THR-β) agonists to reduce hepatic lipid accumulation, farnesoid X receptor (FXR) agonists to regulate bile acid and lipid metabolism, peroxisome proliferator-activated receptor (PPAR) agonists to address inflammation and fibrosis, GLP-1 receptor agonists (GLP-1RAs) to improve metabolic parameters, fibroblast growth factor 21 (FGF21) analogs to modulate energy metabolism, and SGLT2 inhibitors to reduce hepatic fat via glucose lowering.
The review also highlights emerging non-pharmacological and biotechnology-based strategies. RNA interference using siRNA offers the possibility of silencing specific disease-driving genes in hepatocytes. Gut microbiome interventions—including targeted probiotics and fecal microbiota transplantation—aim to correct dysbiosis linked to MASH pathogenesis. Stem cell therapies represent a longer-horizon approach to liver regeneration and repair.
A key theme is that no single-target drug has proven sufficient; the field is moving toward rational combination regimens that simultaneously address lipotoxicity, inflammation, and fibrosis. Ongoing clinical trials are expected to clarify optimal combinations and sequencing.
Important caveats include the review's reliance on abstract-level evidence for many candidates, the high attrition rate of MASH drug trials, and the acknowledged gaps in long-term safety data and validated non-invasive biomarkers needed to guide treatment decisions.
Key Findings
- Six major drug target pathways identified for MASH: THR-β, FXR, PPAR, GLP-1RA, FGF21, and SGLT2.
- Gene silencing via siRNA shows early promise as a precision approach to MASH treatment.
- Gut microbiome interventions—probiotics and fecal microbiota transplantation—are emerging as viable MASH strategies.
- Multi-targeted combination therapies addressing fibrosis, inflammation, and lipid metabolism appear most likely to succeed.
- Non-invasive diagnostics and long-term safety data remain critical unmet needs in MASH management.
Methodology
This is a narrative review article summarizing the current therapeutic landscape for MASH based on published literature and ongoing clinical trials. No original experimental data were generated. Conclusions are drawn from synthesized preclinical and clinical evidence across multiple drug classes and intervention modalities.
Study Limitations
The review is based only on the abstract, limiting depth of critical appraisal. As a narrative review, it may not capture the full evidence base or risk of bias across cited studies. Many highlighted therapies remain in early-to-mid clinical trial stages with unproven long-term safety and efficacy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.